Nature Reviews Gastroenterology & Hepatology - Table of Contents alert Volume 14 Issue 2

If you are unable to see the message below, click here to view.

Advertisement
Nature Outlook: Inflammatory Bowel Disease (IBD)  For certain infections, faecal transplants have resulted in remarkable recoveries. Will the same ever be true for people with IBD? It's a condition on the rise in Asia, but why? Follow those trying to find out, and learn how our environments influence IBD in this Outlook.  Access the Outlook Produced with support from  Salix Pharmaceuticals
TABLE OF CONTENTS
February 2017 Volume 14 Number 2
2015 2-year Impact Factor 14.435 Journal Metrics 2-year Median 8	In this issue Research Highlights Year in Review Reviews Also this month  Featured article: Imaging in pancreatic disease Julien Dimastromatteo, Teresa Brentnall & Kimberly A. Kelly
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
NW Missouri Private Practice Seeks BC/BE Gastroenterologist Well-established GI practice Early partnership track Well trained group of physicians at institutions such as Cleveland Clinic/Harvard. We offer full gamut of GI services including ERCP and EUS Interested candidates Contact cadkinsgi@gmail.com or 816-232-0185 Click here to learn more
Advertisement
Open for Submissions A new open access, multi-and interdisciplinary journal dedicated to publishing the finest research on both microbial biofilms and microbiomes, the journal is now open for submissions. Explore the benefits of submitting your next research article.
RESEARCH HIGHLIGHTS Top Gut microbiota: Intestinal microbiota oscillations regulate host circadian physiology Published online: 21 December 2016 p67 | doi:10.1038/nrgastro.2016.205 PDF Pancreatic cancer: Pancreatic tumours derive amino acids via extracellular protein uptake Published online: 18 January 2017 p68 | doi:10.1038/nrgastro.2017.3 PDF IN BRIEF Development: Modelling human stomach development with gastric organoids | Alcoholic liver disease: Alcoholic hepatitis: a warning for prednisolone and infection risk? | Therapy: Experimental portal hypertension — pinning hopes on FXR agonists? PDF
YEAR IN REVIEW		Top
Gut–brain axis in 2016: Brain–gut–microbiota axis — mood, metabolism and behaviour Timothy G. Dinan & John F. Cryan Published online: 05 January 2017 p69 | doi:10.1038/nrgastro.2016.200 In 2016, key studies have increased our understanding of the part played by the brain–gut–microbiota axis in disorders as diverse as depression, obesity and autism spectrum disorder. The data indicate that alterations in gut-microbial composition can substantially affect central physiology, and that transplantation of the gut microbiota can transfer a behavioural or physiological phenotype. Full Text | PDF
HBV in 2016: Global and immunotherapeutic insights into hepatitis B Mala K. Maini & Antonio Bertoletti Published online: 05 January 2017 p71 | doi:10.1038/nrgastro.2016.196 The burden of HBV infection remains high and new strategies to improve HBV vaccination and therapy are needed. Key research in 2016 highlights the efficacy of current approaches and proposes new concepts for some of the immunological defects that need to be overcome for HBV functional cure. Full Text | PDF
Liquid biopsy in 2016: Circulating tumour cells and cell-free DNA in gastrointestinal cancer Klaus Pantel & Catherine Alix-Panabières Published online: 18 January 2017 p73 | doi:10.1038/nrgastro.2016.198 The challenge to obtain needle biopsy samples from patients with cancer has steered the development of new blood-based diagnostics called 'liquid biopsy'. In 2016, major advances have been made in the use of circulating tumour cells and cell-free DNA for monitoring tumour evolution in patients with cancer of the gastrointestinal tract, with a focus on colorectal cancer. Full Text | PDF
IBD in 2016: Biologicals and biosimilars in IBD — the road to personalized treatment Krisztina B. Gecse & Péter L. Lakatos Published online: 11 January 2017 p74 | doi:10.1038/nrgastro.2016.206 In 2016, personalized medicine for IBD has been evolving. Increasing comfort with biosimilar infliximab was achieved with 'real-life' data. Drugs with alternative modes of action confirmed substantial benefit, even in patients failing anti-TNF agents. Adipose-derived mesenchymal stem cells yielded a new treatment option for perianal fistulas. Full Text | PDF
Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances Gwilym J. Webb & Gideon M. Hirschfield Published online: 11 January 2017 p76 | doi:10.1038/nrgastro.2016.201 In 2016, obeticholic acid became the first new licensed therapy for primary biliary cholangitis in >20 years. This therapeutic came at a time of improved disease understanding from biliary and immunological mechanistic insights. Full Text | PDF
Gut microbiota in 2016: A banner year for gut microbiota research Wendy S. Garrett Published online: 11 January 2017 p78 | doi:10.1038/nrgastro.2016.207 Fascination about the gut microbiota shows no signs of slowing down. The launch of the US National Microbiome Initiative in 2016, and similar efforts across the globe, underscore the continued enthusiasm for microbiome studies in the USA and beyond. Indeed, 2016 has been yet another notable year for gut microbiota research. Full Text | PDF
REVIEWS		Top
Developmental origins of NAFLD: a womb with a clue Stephanie R. Wesolowski, Karim C. El Kasmi, Karen R. Jonscher & Jacob E. Friedman Published online: 26 October 2016 p81 | doi:10.1038/nrgastro.2016.160 Here, the authors comprehensively explore evidence that maternal obesity and/or obesogenic diet, mediated by factors such as altered maternal metabolism, microbiota colonization, macrophage programming and epigenetic changes, can programme NAFLD risk and disease progression in offspring. Current and potential clinical interventions are also discussed. Abstract | Full Text | PDF
Imaging in pancreatic disease Julien Dimastromatteo, Teresa Brentnall & Kimberly A. Kelly Published online: 09 November 2016 p97 | doi:10.1038/nrgastro.2016.144 Effective diagnostic imaging can improve prognosis for patients with pancreatic diseases such as pancreatitis, pancreatic cancer and diabetes mellitus, which benefit from early treatment. Here, Kelly and colleagues review current and future technologies for imaging pancreatic disease, and discuss the development of new contrast agents and molecular imaging targets. Abstract | Full Text | PDF
Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes Siddharth Singh et al. Published online: 30 November 2016 p110 | doi:10.1038/nrgastro.2016.181 Obesity affects 15–40% of patients with IBD. Here, Singh and colleagues discuss the evidence linking obesity to IBD pathogenesis, the effect of obesity on disease outcomes and treatment response, and obesity-related issues in abdominal imaging and IBD surgery. Abstract | Full Text | PDF
Global epidemiology and burden of HCV infection and HCV-related disease Aaron P. Thrift, Hashem B. El-Serag & Fasiha Kanwal Published online: 07 December 2016 p122 | doi:10.1038/nrgastro.2016.176 Chronic HCV infection is a global health problem. In this Review, the authors describe the global burden of hepatitis C and HCV-related disease, including hepatocellular carcinoma, cirrhosis and extrahepatic manifestations. How the new direct-acting antiviral agents might influence disease burden is also discussed. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.